Amylyx Pharmaceuticals (AMLX) Treasury Shares (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Treasury Shares of $3.9 million for Q1 2026, up 23.92% year-over-year from $3.2 million in Q1 2025, and up 44.33% quarter-over-quarter from $2.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Treasury Shares (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Treasury Shares history runs 6 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Treasury Shares rose 23.92% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 23.92% YoY), while the FY2025 annual figure was $2.7 million, up 23.15% from the prior year.
- Treasury Shares for Q1 2026 stood at $3.9 million, up from $2.7 million in the prior quarter.
- The five-year high for Treasury Shares was $3.9 million in Q1 2026, with the low at $596709.0 in Q1 2022.
- The 5-year median for Treasury Shares is $2.1 million (2024), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2024: Treasury Shares sank 98.0% in 2022, then surged 174.08% in 2024.
- Amylyx Pharmaceuticals' Treasury Shares stood at $740297.0 in 2022, then surged by 50.28% to $1.1 million in 2023, then jumped by 98.91% to $2.2 million in 2024, then gained by 23.15% to $2.7 million in 2025, then soared by 44.33% to $3.9 million in 2026.
- Business Quant data shows AMLX's Treasury Shares at $3.9 million in Q1 2026, $2.7 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 4.13 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 1.30 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -297.63 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 35.35 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 19.00 Mn |
| 10 | Amylyx Pharmaceuticals | 4.39 Bn | 4.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.86 Mn |
| Jun 30, 2026 | 3.86 Mn |
| Mar 31, 2026 | 3.93 Mn |
| Mar 31, 2026 | 3.93 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 3.14 Mn |
| Jun 30, 2025 | 3.14 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 2.06 Mn |
| Mar 31, 2024 | 2.06 Mn |